Experiences with

Ergot

According to the FDA notice, the non-ergot dopamine agonist will be discontinued in its tablet form as well as some of its extended-release tablet formulations. The therapy is anticipated to cease availability of these forms by May 2023.

These are developed in laboratories and may be synthetic or very often derived from natural substances, e.g. opioids, ergot-derived dopamine agonists. They are legally regulated as controlled drugs, prescribable drugs or as (approved) over the counter medicines.

The underlying mechanisms of this pattern of breathing abnormality in PD are not fully understood but are likely to include a combination of factors: increased chest wall rigidity; a reduction in lung volume secondary to stooped posture; and lung changes secondary to ergot-derived dopamine agonist drugs

In addition, the ergot-derived dopamine agonists can cause pleural and pulmonary fibrosis. https://www.ncbi.nlm.nih.gov/pubmed/7867286 Doctors tell me that I have paralyzed phrenic nerve effecting one lung, on my right side. I had PFT-Pulmonary Function Test over one year ago.